| | Journey to the East: U.S. derm leads volunteers in Cambodia
| | International report — Robert E. Kalb, M.D., made giving back a family adventure four years ago, when he, his wife and two college-aged children took their first medical mission trip with Health Volunteers Overseas to Phnom Penh, Cambodia. | |  |
|
|
| Journey to the East: U.S. derm leads volunteers in Cambodia
| | | International report — Robert E. Kalb, M.D., made giving back a family adventure four years ago, when he, his wife and two college-aged children took their first medical mission trip with Health Volunteers Overseas to Phnom Penh, Cambodia. |
| | Fillers with lidocaine ease injection sting
| | | New York — Approved by the Food and Drug Administration, a number of fillers containing lidocaine hit the market this spring and are quickly coming into fairly widespread use. Arielle Kauvar, M.D., director of the New York Laser & Skin Care Center, says she started using them in March, and unless a patient is allergic to lidocaine, she sees no reason now to use fillers without the anesthetic already included. |
| | Dysport brings choice to cosmetic dermatology marketplace
| | | San Francisco — Clinicians have to apply different ratios when using Dysport (abobotulinumtoxinA, Medicis) in their patients, according to a clinical professor of dermatology at the University of California School of Medicine, San Francisco. |
| | Accurate diagnosis of infantile birthmarks crucial to avoid complications
| | | San Francisco — Vascular birthmarks are very ccommon in newborns, and some varieties affect up to 50 percent of babies. But the challenge for dermatologists can be the early diagnosis and the ability to distinguish the subtle differences between a banal birthmark and one that calls for quick action. |
| | Oncolytic vaccine therapy shows promise in melanoma, SCC studies
| | | National report — Efficacy and safety results of phase 2 studies provide support for undertaking pivotal trials investigating an oncolytic vaccine therapy, granulocyte colony-stimulating factor (GM-CSF)-encoding oncolytic herpes simplex virus (OncoVEX GM-CSF, BioVex), for treating metastatic melanoma (MM) and head and neck squamous cell carcinoma (SCC). |
|
| 
Practice Tools
